pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
HER2 · news · pharmadog
← back to HER2
News · HER2
124
stories
8d
Four questions on new safety warnings for Neurocrine’s Vykat XR
endpoints
10d
FDA rejects ITM's radiopharma drug over manufacturing problems
endpoints
16d
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
17d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
27d
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
28d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
28d
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
biospace
29d
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
endpoints
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 21, 26
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
Jul 15, 26
Celcuity gains FDA approval for closely watched breast cancer drug
biopharma dive
Jul 14, 26
Draig nets $65M to advance depression drug aimed at rebuilding synapses
endpoints
Jul 10, 26
The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy
endpoints
Jul 9, 26
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
endpoints
Jul 9, 26
GSK walks away from Alector pact as immuno-neurology bet fizzles
endpoints
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 2, 26
Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist
endpoints
Jun 18, 26
Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs
endpoints
Jun 15, 26
Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff
endpoints
Jun 10, 26
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
endpoints
Jun 10, 26
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
endpoints
Jun 4, 26
A Spanish biotech banks $87M to make differentiated ADCs
biopharma dive
Jun 2, 26
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
biopharma dive
Jun 2, 26
Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
endpoints
Jun 1, 26
Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
endpoints
May 15, 26
FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer
onclive
May 14, 26
#ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndrome
endpoints
May 14, 26
Create Medicines raises $122M to bolster in vivo CAR-T therapies
biopharma dive
May 14, 26
Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question
onclive
← prev
page 1 of 5
next →
